Patient-derived xenograft (PDX) mouse models represent a growing class of models to study human cancers. These models, which are based on a variety of backgrounds, function as a tool to evaluate the interaction between a specific tumor and treatment. In a recent article in Biocompare, Taconic Biosciences' Dr. Terina Martinez and Dr. Megan MacBride highlight mouse models used for PDX studies such as nude mice, severe combined immunodeficient (SCID) mice, genetically engineered models (GEMs), and the triple immunodeficient mouse known as the CIEA NOG mouse®:
"Over 50 years ago, scientists took a primary colonic adenocarcinoma from a 74-year-old patient, diced it up, and injected it under the skin of immune deficient mice. The tumors grew over several weeks and were then transplanted to another set of mice. The researchers, Rygaard and Povlsen, showed that the tumors retained many characteristics of the original human one. However, getting the tumors to grow in mice wasn't necessarily an easy task. Of the four tumors they injected, two breast carcinomas and two colon carcinomas, only one took."
Read more at: biocompare.com
"Over 50 years ago, scientists took a primary colonic adenocarcinoma from a 74-year-old patient, diced it up, and injected it under the skin of immune deficient mice. The tumors grew over several weeks and were then transplanted to another set of mice. The researchers, Rygaard and Povlsen, showed that the tumors retained many characteristics of the original human one. However, getting the tumors to grow in mice wasn't necessarily an easy task. Of the four tumors they injected, two breast carcinomas and two colon carcinomas, only one took."